#ASH20 Al­lo­gene's David Chang makes the case for an off-the-shelf CAR-T in the jam packed an­ti-BC­MA field

It’s hard to make a big mark in the an­ti-BC­MA field.

The CAR-T JNJ-4528 from J&J and Chi­na’s Leg­end has been hog­ging the head­lines re­cent­ly with stel­lar re­sults for ad­vanced mul­ti­ple myelo­ma, steadi­ly ad­vanc­ing on the strug­gling ide-cel (bb2121) pro­gram from Bris­tol My­ers Squibb and blue­bird. And then there’s a pas­sel of ri­vals hus­tling up every­thing from CAR-Ts to bis­pecifics and AD­Cs.

But Al­lo­gene $AL­LO is try­ing hard to give them a run for the mon­ey.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER